Literature DB >> 23552902

Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm.

Masami Nishino1, Naoki Mori, Takahiro Yoshimura, Daisuke Nakamura, Yasuharu Lee, Masayuki Taniike, Nobuhiko Makino, Hiroyasu Kato, Yasuyuki Egami, Ryu Shutta, Jun Tanouchi, Yoshio Yamada.   

Abstract

It has been reported that a major cause of coronary vasospastic angina (VSA) is endothelial dysfunction of the coronary artery. On the other hand, some studies showed that serum uric acid and lipoprotein(a) are correlated with endothelial dysfunction. Thus, we examined whether uric acid and lipoprotein(a), are correlated with VSA. Four hundred forty-one patients with suspected VSA who underwent a coronary angiogram with acetylcholine provocation (ACh test) during an 8-year period were enrolled. We divided them into a VSA group, who showed coronary spasm by the ACh test, and an atypical chest pain (ACP) group, who showed negative ACh test. We compared serum markers between the two groups, including low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, high-sensitivity C-reactive protein (hs-CRP), lipoprotein(a), fibrinogen, total plasminogen activator inhibitor-1, and uric acid. Uric acid, hs-CRP, and lipoprotein(a) were significantly higher in the VSA group than in the ACP group (all P < 0.05) while there were no significant differences in the other parameters. Multivariate analyses identified uric acid and lipoprotein(a) as significant independent markers for VSA. Uric acid and lipoprotein(a) are correlated with VSA, and medical intervention to decrease uric acid and lipoprotein(a) might be effective in controlling VSA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23552902     DOI: 10.1007/s00380-013-0346-x

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  40 in total

1.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

2.  Nitric oxide-mediated flow-dependent dilation is impaired in coronary arteries in patients with coronary spastic angina.

Authors:  K Kugiyama; M Ohgushi; T Motoyama; S Sugiyama; H Ogawa; M Yoshimura; Y Inobe; O Hirashima; H Kawano; H Soejima; H Yasue
Journal:  J Am Coll Cardiol       Date:  1997-10       Impact factor: 24.094

3.  New light on a forgotten disease: vasospastic angina.

Authors:  Filippo Crea; Gaetano Antonio Lanza
Journal:  J Am Coll Cardiol       Date:  2011-09-13       Impact factor: 24.094

4.  Long-term prognosis for patients with variant angina and influential factors.

Authors:  H Yasue; A Takizawa; M Nagao; S Nishida; M Horie; J Kubota; S Omote; K Takaoka; K Okumura
Journal:  Circulation       Date:  1988-07       Impact factor: 29.690

5.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.

Authors:  J W McLean; J E Tomlinson; W J Kuang; D L Eaton; E Y Chen; G M Fless; A M Scanu; R M Lawn
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

6.  Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina.

Authors:  K Kugiyama; H Yasue; K Okumura; H Ogawa; K Fujimoto; K Nakao; M Yoshimura; T Motoyama; Y Inobe; H Kawano
Journal:  Circulation       Date:  1996-08-01       Impact factor: 29.690

7.  Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial.

Authors:  Awsan Noman; Donald S C Ang; Simon Ogston; Chim C Lang; Allan D Struthers
Journal:  Lancet       Date:  2010-06-09       Impact factor: 79.321

8.  Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk.

Authors:  Giuseppe Mercuro; Cristiana Vitale; Elena Cerquetani; Sandra Zoncu; Martino Deidda; Massimo Fini; Giuseppe M C Rosano
Journal:  Am J Cardiol       Date:  2004-10-01       Impact factor: 2.778

9.  Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis.

Authors:  K A Hajjar; D Gavish; J L Breslow; R L Nachman
Journal:  Nature       Date:  1989-05-25       Impact factor: 49.962

10.  Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease.

Authors:  Ticiana C Rodrigues; David M Maahs; Richard J Johnson; Diana I Jalal; Gregory L Kinney; Christopher Rivard; Marian Rewers; Janet K Snell-Bergeon
Journal:  Diabetes Care       Date:  2010-08-26       Impact factor: 17.152

View more
  13 in total

1.  Effect of serum uric acid on the positive predictive value of dobutamine stress echocardiography.

Authors:  Alpay Aribas; Hakan Akilli; Mehmet Kayrak; Hayrudin Alibasic; Oguzhan Yildirim; Ahmet Lutfi Sertdemir; Mustafa Karanfil; Kurtulus Ozdemir
Journal:  Heart Vessels       Date:  2014-12-11       Impact factor: 2.037

2.  Maximal acetylcholine dose of 200 μg into the left coronary artery as a spasm provocation test: comparison with 100 μg of acetylcholine.

Authors:  Shozo Sueda; Hiroaki Kohno; Toru Miyoshi; Tomoki Sakaue; Yasuhiro Sasaki; Hirokazu Habara
Journal:  Heart Vessels       Date:  2014-09-02       Impact factor: 2.037

3.  Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction.

Authors:  Takayuki Mitsuda; Yusuke Uemura; Hideki Ishii; Kenji Takemoto; Tomohiro Uchikawa; Masayoshi Koyasu; Shinji Ishikawa; Ayako Miura; Ryo Imai; Satoshi Iwamiya; Yuta Ozaki; Tomohiro Kato; Rei Shibata; Masato Watarai; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2016-03-02       Impact factor: 2.037

4.  Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population.

Authors:  Eiji Oda
Journal:  Heart Vessels       Date:  2013-06-28       Impact factor: 2.037

5.  Serum uric acid levels and long-term outcomes in chronic kidney disease.

Authors:  Tokiko Miyaoka; Toshio Mochizuki; Takashi Takei; Ken Tsuchiya; Kosaku Nitta
Journal:  Heart Vessels       Date:  2013-08-09       Impact factor: 2.037

6.  Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm.

Authors:  Ken Watanabe; Tetsuro Shishido; Yoichiro Otaki; Tetsu Watanabe; Takayuki Sugai; Taku Toshima; Tetsuya Takahashi; Miyuki Yokoyama; Daisuke Kinoshita; Takayo Murase; Takashi Nakamura; Masahiro Wanezaki; Harutoshi Tamura; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; So Yamauchi; Tamon Yamanaka; Takuya Miyamoto; Isao Kubota; Masafumi Watanabe
Journal:  Heart Vessels       Date:  2018-06-23       Impact factor: 2.037

7.  Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients.

Authors:  Mitsuru Masaki; Toshiaki Mano; Akiyo Eguchi; Shohei Fujiwara; Masataka Sugahara; Shinichi Hirotani; Takeshi Tsujino; Kazuo Komamura; Masahiro Koshiba; Tohru Masuyama
Journal:  Heart Vessels       Date:  2016-01-29       Impact factor: 2.037

8.  Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study.

Authors:  Sylvie Perreault; Javier Nuevo; Scott Baumgartner; Robert Morlock
Journal:  World J Nephrol       Date:  2017-05-06

Review 9.  The Biochemical Markers Associated with the Occurrence of Coronary Spasm.

Authors:  Liang Li; Yong-Ping Jin; Shu-Dong Xia; Chao Feng
Journal:  Biomed Res Int       Date:  2019-09-17       Impact factor: 3.411

10.  Association between the Red Cell Distribution Width and Vasospastic Angina in Korean Patients.

Authors:  Mi-Hyang Jung; Dong Il Shin; Ik Jun Choi; Suk Min Seo; Sooa Choi; Mahn Won Park; Pum-Joon Kim; Sang Hong Baek; Ki-Bae Seung
Journal:  Yonsei Med J       Date:  2016-05       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.